Denali Therapeutics Inc
Denali Therapeutics Inc (DNLI) Unusual Options Activity Today
DNLI's highest volume power reading is 1.11%, on the $20 PUT expiring Dec 18, 2026. This strike traded 7 contracts against just 632 in open interest. On the call side, the highest reading is the $22.5 CALL expiring Dec 18, 2026 at 27.62%, with 227 contracts traded against 822 open, as of Nov 20, 2026.
Read more
Checking DNLI unusual options activity helps you spot when traders are making outsized bets on Denali Therapeutics Inc before the broader market catches on. Unusual activity flags contracts trading at multiples of their average daily volume, often signaling informed money positioning ahead of a catalyst. Use our scanner to monitor DNLI unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically means volume vastly exceeds open interest at a given strike, or total contract volume on a name spikes well above its norm. Watching DNLI unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking DNLI unusual options volume across calls and puts helps you separate hedging from genuinely speculative positioning, especially valuable around earnings, product launches, and macro events.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.
| 22.50 | 0.50 | 2.30 | 1.40 | 134% | 227 | 822 | 27.62% |
| 20.00 | — | 2.45 | 2.45 | 150% | 15 | 592 | 2.53% |
| 25.00 | — | 2.25 | 2.25 | 206% | 1 | 121 | 0.83% |
| 2.50 | 13.90 | 18.20 | 16.05 | 401% | 0 | 0 | — |
| 5.00 | 11.40 | 15.70 | 13.55 | 258% | 0 | 0 | — |
| 20.00 | 0.70 | 4.00 | 2.35 | 71% | 7 | 632 | 1.11% |
| 2.50 | — | 0.75 | 0.75 | 698% | 0 | 0 | — |
| 5.00 | — | 3.40 | 3.40 | 978% | 0 | 0 | — |
| 7.50 | — | 3.00 | 3.00 | 600% | 0 | 11 | 0.00% |
| 10.00 | — | 0.95 | 0.95 | 254% | 0 | 2,113 | 0.00% |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →